Clinical Trial Update: Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ALLN-177 to reduce urinary oxalate excretion in adults with hyperoxaluria and kidney stones has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Nephrolithiasis

Drugs mentioned

• ALLN-177

Snippet

Sponsor: Allena Pharmaceuticals | Conditions: Hyperoxaluria, Nephrolithiasis | Phase 2 | Status: COMPLETED | Results posted: 2016-04-27